3176 Stock Overview
A biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Medigen Biotechnology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.75 |
| 52 Week High | NT$48.20 |
| 52 Week Low | NT$29.50 |
| Beta | 0.61 |
| 1 Month Change | 2.99% |
| 3 Month Change | -11.01% |
| 1 Year Change | -19.83% |
| 3 Year Change | -37.74% |
| 5 Year Change | -44.68% |
| Change since IPO | 71.47% |
Recent News & Updates
Shareholder Returns
| 3176 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.8% | -1.7% | 2.2% |
| 1Y | -19.8% | 14.8% | 27.7% |
Return vs Industry: 3176 underperformed the TW Biotechs industry which returned 14.8% over the past year.
Return vs Market: 3176 underperformed the TW Market which returned 27.7% over the past year.
Price Volatility
| 3176 volatility | |
|---|---|
| 3176 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 3176 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 3176's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Shun-Lang Chang | www.medigen.com.tw |
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States.
Medigen Biotechnology Corp. Fundamentals Summary
| 3176 fundamental statistics | |
|---|---|
| Market cap | NT$4.56b |
| Earnings (TTM) | -NT$412.89m |
| Revenue (TTM) | NT$1.41b |
3.2x
P/S Ratio-11.0x
P/E RatioIs 3176 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3176 income statement (TTM) | |
|---|---|
| Revenue | NT$1.41b |
| Cost of Revenue | NT$609.58m |
| Gross Profit | NT$803.51m |
| Other Expenses | NT$1.22b |
| Earnings | -NT$412.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.96 |
| Gross Margin | 56.86% |
| Net Profit Margin | -29.22% |
| Debt/Equity Ratio | 13.6% |
How did 3176 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 22:38 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigen Biotechnology Corp. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Yijun Chen | SinoPac Securities Investment Service |
| Pravin Gondhale | Virtua Research Inc. |